The Fiscal Year 2013 (FY13) Defense Appropriations Act provides for $3.2 million (M) to the Department of Defense Duchenne Muscular Dystrophy Research Program (DMDRP) to support innovative, high-impact Duchenne muscular dystrophy research. This program is administered by the US Army Medical Research and Materiel Command through the Office of the Congressionally Directed Medical Research Programs (CDMRP).

The DMDRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications. FY13 DMDRP Program Announcement and General Application Instructions for the following award mechanism are anticipated to be posted on the website in May 2013. Pre-application and application deadlines will be available when the Program Announcement is released. This pre-announcement should not be construed as an obligation by the government.

Focus Areas: The FY13 DMDRP encourages research projects that specifically address the critical needs of the Duchenne muscular dystrophy community in the following Focus Areas:

  • Extension or expansion of preclinical translational data in support of the therapeutic development path (including independent replication and comparative studies)
  • Developing clinical biomarkers to improve evaluation of diagnosis, disease severity, disease progression, and/or response to treatment
  • Assessment of clinical trial outcomes (invasive and non-invasive), such as:
    • Molecular, functional, imaging, etc.
    • Evaluating surrogate markers
    • Evaluating potential composite scores for outcomes assessment
    • Patient outcomes, e.g., quality of life, activities of daily living, etc.
  • Novel interventions that could improve clinical care and quality of life in the near term

Award Mechanism


Key Mechanism Elements


Investigator-Initiated Research Award Principal Investigator: Must be at or above the level of Assistant Professor (or equivalent).
Optional Qualified Collaborator: Must be at or above the level of Assistant Professor (or equivalent).
Optional Nested Resident or Medical Student Trainee: Resident trainee must be enrolled in an accredited residency program. Medical student trainee must be enrolled in a nationally accredited (or equivalent) medical school. Trainees must be able to devote a minimum of 40% level of effort.
  • Supports translational research that will have an impact on extending and improving the function, quality of life, and lifespan for all individuals diagnosed with DMD.
  • Preliminary data required.
  • Maximum funding of $525,000 in direct costs (plus indirect costs) or $675,000 in direct costs if requesting an Optional Collaborator.
  • Period of performance should not exceed 3 years.
  • Nested traineeship: Additional maximum of $75,000 for residents or $55,000 for medical students in direct and indirect costs over a one-year period of performance.

All applications must conform to the final program announcement and general application instructions that will be available for electronic downloading from the website. The application package containing the required forms for the award mechanism will also be found on A listing of all USAMRMC funding opportunities can be obtained on the website by performing a basic search using CFDA Number 12.420.

A pre-application is required and must be submitted through the CDMRP eReceipt website ( prior to the pre-application deadline. Applications must be submitted through the federal government’s single-entry portal, Submission deadlines are not available until the program announcements are released. Requests for email notification of the program announcement release may be sent to For more information about the DMDRP or other CDMRP-administered programs, please visit the CDMRP website (

Point of Contact:

Related Posts

Share This Page

Make an Impact

You can advance the care, treatment and cure for Duchenne muscular dystrophy. Contributions in any amount can truly make a difference and can be credited to a fundraiser or event from the list below.